Hypertrophic cardiomyopathy (HCM) is an autosomal dominant cardiac disorder, characterized by primary left ventricular hypertrophy (LVH), which may result in sudden death secondary to ventricular arrhythmia particularly in the young or diastolic heart failure at any age. Cardiac magnetic resonance imaging (MRI) allows quantification of myocardial thickness, function, left ventricular outflow tract obstruction, and myocardial scarring. Right ventricular hypertrophy and scarring in HCM is not widely documented. A 37-year-old male, with known HCM, presented complaining of intermittent palpitations and occasional light headedness, without exertional symptoms. Electrocardiogram demonstrated LVH by voltage, (Panel A) confirmed by echocardiogram (Panel B). Cardiac MRI demonstrated asymmetric septal hypertrophy (2.2 cm), right ventricular apical (1.4 cm), and lateral (1.3 cm) wall hypertrophy (Panels C -E). Following intravenous gadolinium (Berlex, Montville, NJ, USA), delayed viability sequences revealed right ventricular apical and lateral myocardial enhancement, along with patchy enhancement of left ventricular apex, basal lateral, and entire septal wall (Panels F -H). Genetic testing revealed a dominant heterozygous missense mutation of the myosin binding protein C (MYBPC3) gene involving a nucleotide change at 13G . C resulting in an amino acid change Gly5Arg. Sequencing of seven other sarcomere genes known to cause HCM, did not detect any pathogenic variants. Right ventricular hypertrophy and scarring has not been previously reported as a phenotype in HCM patients with MYBPC3 mutation. This adds to the spectrum of phenotypic diversity seen in HCM patients with MYBPC3 mutations. Magnetic resonance imaging may be a useful modality to characterize phenotypic morphology in gene-positive HCM.
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(A) The electrocardiogram demonstrates normal sinus rhythm with left ventricular hypertrophy by voltage. (B) Transthoracic echocardiogram in a four-chamber view demonstrates left and right ventricular hypertrophy with no focal wall motion abnormality and preserved ejection fraction. (C-E) MRI true FISP (fast imaging with steady state precession) short axis (C), four-chamber (D), and three-chamber (E) views prior to intravenous contrast administration. There is evidence of right ventricular and left ventricular hypertrophy. The left ventricular end-diastolic and end-systolic volumes were 133 and 42 mL, respectively. The right ventricular end-diastolic and end-systolic volumes were 101 and 57 mL, respectively. The left and right ventricular myocardial mass were 137 and 47 g, respectively.
(F) MRI magnitude (F) image, in the four-chamber view, acquired 10 min following intravenous gadolinium administration. There is contrast enhancement identified within the septal wall and the right ventricular free wall (arrows), both in a mid-myocardial distribution. This enhancement is consistent with myocardial scarring in a pattern that is typical for a cardiomyopathy, which in this case is HCM. (G and H ) MRI magnitude (G and H ) images, in the short axis (G) and the three-chamber view (H ), acquired 10 min following intravenous gadolinium administration. There is contrast enhancement identified within the septal wall, inferior wall, right ventricular free wall insertion sites, and right ventricular free wall (arrows). Again this enhancement is consistent with myocardial scarring.
